Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
NeuBase Therapeutics, Inc is a biotechnology business based in the US. NeuBase Therapeutics shares (NBSE) are listed on the NASDAQ and all prices are listed in US Dollars. NeuBase Therapeutics employs 15 staff and has a market cap (total outstanding shares value) of USD$152.6 million.
|Latest market close||USD$8.43|
|52-week range||USD$4.523 - USD$11.78|
|50-day moving average||USD$7.9934|
|200-day moving average||USD$8.3143|
|Wall St. target price||USD$15.67|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-0.122|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-11)||9.91%|
|1 month (2020-12-22)||8.08%|
|3 months (2020-10-18)||N/A|
|6 months (2020-07-18)||N/A|
|1 year (2020-01-18)||N/A|
|2 years (2019-01-18)||6,501.41%|
|3 years (2018-01-18)||2,267.98%|
|5 years (2016-01-18)||N/A|
|Gross profit TTM||USD$0|
|Return on assets TTM||-45.42%|
|Return on equity TTM||-84.14%|
|Market capitalisation||USD$152.6 million|
TTM: trailing 12 months
There are currently 1.1 million NeuBase Therapeutics shares held short by investors – that's known as NeuBase Therapeutics's "short interest". This figure is 2.9% up from 1.1 million last month.
There are a few different ways that this level of interest in shorting NeuBase Therapeutics shares can be evaluated.
NeuBase Therapeutics's "short interest ratio" (SIR) is the quantity of NeuBase Therapeutics shares currently shorted divided by the average quantity of NeuBase Therapeutics shares traded daily (recently around 182817.87439614). NeuBase Therapeutics's SIR currently stands at 6.21. In other words for every 100,000 NeuBase Therapeutics shares traded daily on the market, roughly 6210 shares are currently held short.
However NeuBase Therapeutics's short interest can also be evaluated against the total number of NeuBase Therapeutics shares, or, against the total number of tradable NeuBase Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case NeuBase Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 NeuBase Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0553% of the tradable shares (for every 100,000 tradable NeuBase Therapeutics shares, roughly 55 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against NeuBase Therapeutics.
Find out more about how you can short NeuBase Therapeutics stock.
We're not expecting NeuBase Therapeutics to pay a dividend over the next 12 months.
NeuBase Therapeutics, Inc., a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders and cancer. Its lead programs include NT0100, a PATrOL enabled anti-gene for Huntington's disease; and NT0200, a PATrOL enabled anti-gene for myotonic dystrophy type 1. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.
Everything we know about the CDT Environmental Technology Investment Holdings Limited IPO, plus information on how to buy in.
Everything we know about the Viant Technology Inc IPO, plus information on how to buy in.
Steps to owning and managing EVGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing ETL, with 24-hour and historical pricing before you buy.
Steps to owning and managing EQBK, with 24-hour and historical pricing before you buy.
Steps to owning and managing EIGI, with 24-hour and historical pricing before you buy.
Steps to owning and managing ELTK, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNKN, with 24-hour and historical pricing before you buy.
Steps to owning and managing DKL, with 24-hour and historical pricing before you buy.
Steps to owning and managing DMAC, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.